Predictors of overall survival (OS) in veterans with non-metastatic castration resistant prostate cancer (nmCRPC).

Fuld, Alexander; Young‐Xu, Yinong; Li, Sophia; Pilon, Dominic; Bhak, Rachel H.; Duchesneau, Emilie; Hellstern, Michael; Kamstra, Rhiannon; Behl, Ajay S.; Lefèbvre, Patrick; Freedland, Stephen J.

doi:10.1200/jco.2018.36.15_suppl.e17057

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the US veteran population the nmCRPC mortality figure was reported as 48% (6,552 deaths) between 2007-2017. 11 mCRPC patients were more than three times more likely to die than nmCRPC patients (HR=3.438; p<0.001). 11 Scher et al 2015…”

Section: Mortalitymentioning

confidence: 96%

“…Four retrospective studies 9,[11][12][13] reported the prevalence of nmCRPC and three retrospective studies 9,11,12 reported on mCRPC (Error! Reference source not found.).…”

Section: Prevalencementioning

confidence: 99%

“…In the US, the estimated prevalence of nmCRPC and mCRPC was 1.1-2.1% (947-13,710 cases) and 2.1% (13,818) of PC cases, respectively, from 2007-2017. 11,13 In the UK, the estimated prevalence of nmCRPC and mCRPC was 12.3% (13,710) and 50.2% (13,818), respectively, between 2007-2017. 11 Two UK-based studies reported the proportion of nmCRPC and mCRPC in the CRPC population as 84.3-91.2% (9,779-27,000) and 8.8-15.7% (1,821-2,600), respectively, between 1998-2009 using THIN and General Practice Research Database (GPRD).…”

Section: Prevalencementioning

confidence: 99%

“…11,13 In the UK, the estimated prevalence of nmCRPC and mCRPC was 12.3% (13,710) and 50.2% (13,818), respectively, between 2007-2017. 11 Two UK-based studies reported the proportion of nmCRPC and mCRPC in the CRPC population as 84.3-91.2% (9,779-27,000) and 8.8-15.7% (1,821-2,600), respectively, between 1998-2009 using THIN and General Practice Research Database (GPRD). 9,12 The UK prevalence reported by Morgan et al 2010 were based on an extrapolation and is higher than the other estimates identified in this review.…”

Section: Prevalencementioning

confidence: 99%

See 3 more Smart Citations

Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations

et al. 2021

View full text Add to dashboard Cite

Section: Mortalitymentioning

confidence: 96%

“…Four retrospective studies 9,[11][12][13] reported the prevalence of nmCRPC and three retrospective studies 9,11,12 reported on mCRPC (Error! Reference source not found.).…”

Section: Prevalencementioning

confidence: 99%

Section: Prevalencementioning

confidence: 99%

Section: Prevalencementioning

confidence: 99%

See 2 more Smart Citations

Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations

et al. 2021

View full text Add to dashboard Cite

“…Так, в США оценочная распространенность мКРРПЖ, согласно результатам указанных исследований, в период с 2007 по 2017 г. составила 2,1%, или 13 818 случаев [16,18].…”

Section: статистика и эпидемиологияunclassified

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer

Огнерубов¹

2021

J. Mod. Onco.

View full text Add to dashboard Cite

The incidence of prostate cancer in the structure of malignant neoplasms occupies the fourth place, it is 7.3%. 1 414 259 new cases and 375 304 deaths were estimated worldwide in 2020. In recent decades, there was a significant increase in the number of cases of metastatic castration-resistant prostate cancer (mCRPC). There is no consensus on the optimal treatment choice, nowadays. The various therapeutic options are offered for these aims. But, the regimes and the consistence of their application are problematical and far from being resolved. The aim of this review is to analyze the studies on the use of cabazitaxel in the treatment of mCRPC. The history of the taxanes application in advanced and metastatic prostate cancer dates back to 2004, when the United States Food and Drug Administration registered docetaxel as first-line therapy for patients with metastatic prostate cancer. Cabazitaxel the new second generation taxane appeared in 2010, and showed the activity in the development of castration resistance. The drug demonstrated high antitumor activity and significant efficacy at the time of progression against the background of treatment with docetaxel and androgen receptor inhibitors. The results of the number of the randomized clinical trials associated with the various aspects of treatment tactics in mCRPC are available for the analysis, nowadays. However, these data and especially the clinical benefit are ambiguous, and sometimes contradictory. The review presents the results of the scientific researches, international clinical studies concerning the various aspects of mCRPC, in particular the choice of modern optimal treatment tactics.

show abstract

Recent Advances and Future Directions in the Management of Metastatic Castration-Resistant Prostate Cancer using Androgen Receptor Signaling Inhibitors and Poly-adipose Polymerase Inhibitors: a Literature Review

2024

IJFMR

View full text Add to dashboard Cite

Prostate cancer is still the most common cancer in men and the second leading cancer-related cause of death in men worldwide. There are several types of prostate cancer. One of which is the metastatic progression of castration-resistant prostate cancer (mCRPC). According to current studies, the mechanism of resistance can be categorized into classical androgen receptor (AR) pathway overexpression, abnormal AR pathway activation, and non-AR pathway. These mechanisms develop overtime to further induce treatment resistance in mCRPC. Development of novel therapeutic treatments is necessary to tackle this issue. Recent studies have been conducted on the combination therapy of androgen receptor signaling inhibitors (ARPi) and poly (ADP-ribose) polymerase inhibitors (PARPi) in treating mCRPC shows a nuanced perspective regarding its efficacy compared to monotherapy. Studies shows the combination therapy has significantly prolong radiographic progression-free survival (rPFS) compared to monotherapy in certain genetic groups. Further research is necessary to fully understand their role in the broader mCRPC treatment landscape.

show abstract

Predictors of overall survival (OS) in veterans with non-metastatic castration resistant prostate cancer (nmCRPC).

Cited by 3 publications

References 0 publications

Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations

Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer

Recent Advances and Future Directions in the Management of Metastatic Castration-Resistant Prostate Cancer using Androgen Receptor Signaling Inhibitors and Poly-adipose Polymerase Inhibitors: a Literature Review

Contact Info

Product

Resources

About